Behrman Capital-backed Emmes, a global, full-service Clinical Research Organization, agreed to acquire Orphan Reach, a CRO specialized in clinical research related to rare diseases. Financial terms were not disclosed. "We are thrilled with the addition of Orphan Reach to the Emmes platform, which we believe greatly augments the Company's BioPharma effort and builds on the recent and successful Neox transaction. Orphan Reach enhances Emmes' momentum and steepens the Company's growth trajectory through expansion of its geographic footprint and customer base, and we look forward to continuing to support the Company as it pursues organic initiatives and additional acquisitions," Grant Behrman, Behrman Capital Managing Partner.